-
BioPharma Dive – AI / Data2 weeks agoMerck’s deal for Terns sparks debate over a possible biotech bidding war
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.
-
BioPharma Dive – AI / Data2 weeks agoFDA clears Denali drug in ‘clear step’ for rare disease biotechs
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance...
-
BioPharma Dive – AI / Data2 weeks agoWave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second...
-
BioPharma Dive – AI / Data2 weeks agoMaze tumbles despite positive data for kidney disease drug
Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.
-
BioPharma Dive – AI / Data2 weeks agoBeam posts positive data on base editing treatment for AATD
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
-
BioPharma Dive – AI / Data2 weeks agoSarepta sees early success with RNAi drugs from Arrowhead
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
-
BioPharma Dive – AI / Data2 weeks agoMerck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as...
BioNTech to shutter Singapore HQ after ‘comprehensive review’
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
